We'd be surprised if Nektar Therapeutics (NASDAQ:NKTR) shareholders haven't noticed that the CEO, President & Director, Howard Robin, recently sold US$132k worth of stock at US$1.00 per share. The eyebrow raising move amounted to a reduction of 11% in their holding.
Nektar Therapeutics Insider Transactions Over The Last Year
Notably, that recent sale by Howard Robin is the biggest insider sale of Nektar Therapeutics shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$0.93. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
Insiders in Nektar Therapeutics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
Does Nektar Therapeutics Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Nektar Therapeutics insiders have about 1.6% of the stock, worth approximately US$2.7m. We prefer to see high levels of insider ownership.
What Might The Insider Transactions At Nektar Therapeutics Tell Us?
Insiders sold Nektar Therapeutics shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 3 warning signs for Nektar Therapeutics (1 doesn't sit too well with us!) that we believe deserve your full attention.
Of course Nektar Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
